Related Experiment Video
Updated: Aug 12, 2026
10:51
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Summary
Niridazole shows genetic activity in yeast, but only when metabolized in a rich growth medium. This suggests the drug requires yeast metabolism to become genotoxic, unlike other tested compounds.
Area of Science:
- Genetics
- Microbiology
- Pharmacology
Background:
- Schistosomiasis is a human parasitic disease treated by drugs like niridazole.
- The genotoxicity of niridazole has not been fully elucidated.
- Yeast models are used to study drug-induced genetic activity.
Purpose of the Study:
- To investigate the genotoxic potential of niridazole in yeast.
- To determine the conditions under which niridazole induces genetic activity.
- To compare niridazole's activity with other known genotoxic agents.
Main Methods:
- Yeast cells were treated with niridazole in different media: rich YPG-medium and phosphate buffer.
- Mitotic recombination was assessed as a measure of genetic activity.
- Experiments included comparisons with AF-2 and SQ18, 506.
Main Results:
- Niridazole induced mitotic recombination in yeast grown in YPG-medium.
- Niridazole did not show genetic activity when yeast cells were treated in phosphate buffer.
- Metabolic activation by yeast appears necessary for niridazole's genotoxicity.
Conclusions:
- Niridazole's genotoxicity is dependent on yeast metabolic conditions.
- The findings suggest niridazole is a pro-mutagen requiring metabolic conversion.
- Yeast metabolism plays a crucial role in activating niridazole's genetic activity.
